Suppr超能文献

KIR 配体 C2 与儿童 ALL 的易感性增加相关,并赋予晚期复发的高风险。

KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse.

机构信息

Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health, Heinrich Heine University, Düsseldorf, Germany;

Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University, Düsseldorf, Germany; and.

出版信息

Blood. 2014 Oct 2;124(14):2248-51. doi: 10.1182/blood-2014-05-572065. Epub 2014 Aug 27.

Abstract

A role for HLA class I polymorphism in childhood acute lymphoblastic leukemia (ALL) has been suggested for many years, but unambiguous associations have not been found. Here, we show that the HLA-C-encoded supertypic epitope C2, which constitutes a high-affinity ligand for the inhibitory natural killer (NK) cell receptor KIR2DL1, is significantly increased in ALL patients (n = 320; P = .005). Stratification for ethnicity and disease subtype revealed a strong association of C2 with B-ALL in German cases (P = .0004). The effect was independent of KIR2DS1 and KIR2DL1 allelic polymorphism and copy number. Analysis of clinical outcome revealed a higher incidence of late relapse (> 2.5 years) with increasing number of C2 alleles (P = .014). Our data establish C2 as novel risk factor and homozygosity for C1 as protective for childhood B-ALL supporting a model in which NK cells are involved in immunosurveillance of pediatric B-ALL via interaction of KIR with HLA-C ligands.

摘要

HLA Ⅰ类等位基因多态性在儿童急性淋巴细胞白血病(ALL)中起作用已被提出多年,但尚未发现明确的相关性。在此,我们发现 HLA-C 编码的超型表位 C2 与抑制性自然杀伤(NK)细胞受体 KIR2DL1 具有高亲和力,在 ALL 患者中显著增加(n=320;P=.005)。按种族和疾病亚型分层显示,德国病例中 C2 与 B-ALL 强烈相关(P=.0004)。该效应独立于 KIR2DS1 和 KIR2DL1 等位基因多态性和拷贝数。临床结果分析显示,随着 C2 等位基因数量的增加,晚期复发(>2.5 年)的发生率更高(P=.014)。我们的数据确立了 C2 作为新的危险因素,C1 纯合子作为儿童 B-ALL 的保护因素,支持 NK 细胞通过 KIR 与 HLA-C 配体相互作用参与小儿 B-ALL 的免疫监视的模型。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验